StemCell Therapy

Schellekens, G. A. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43, 155163 (2000).

CAS PubMed Article Google Scholar

Suzuki, K. et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand. J. Rheumatol. 32, 197204 (2003).

CAS PubMed Article Google Scholar

Mishima, S. et al. Higher PGD(2) production by synovial mast cells from rheumatoid arthritis patients compared with osteoarthritis patients via miR-199a-3p/prostaglandin synthetase 2 axis. Sci. Rep. 11, 5738 (2021).

ADS CAS PubMed PubMed Central Article Google Scholar

McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429442 (2007).

CAS PubMed Article Google Scholar

Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 117, 244279 (2008).

CAS PubMed Article Google Scholar

Burmester, G. R. & Pope, J. E. Novel treatment strategies in rheumatoid arthritis. Lancet 389, 23382348 (2017).

PubMed Article Google Scholar

Weinblatt, M. E. Methotrexate in rheumatoid arthritis: A quarter century of development. Trans. Am. Clin. Climatol. Assoc. 124, 16 (2013).

PubMed PubMed Central Google Scholar

Dey, M., Zhao, S. S. & Moots, R. J. Anti-TNF biosimilars in rheumatology: The end of an era?. Expert Opin. Biol. Ther. 21, 2936 (2021).

CAS PubMed Article Google Scholar

Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685699 (2020).

CAS PubMed Article Google Scholar

Garca, C. C., Lefvre, A. & Busnel, J.-M.R. Development of a flow cytometry-based functional assay to study anti-TNF mechanisms of action and capture donor heterogeneity. ImmunoHorizons 4, 648658 (2020).

PubMed Article CAS Google Scholar

Laffon, A. et al. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. 88, 546552 (1991).

CAS PubMed PubMed Central Article Google Scholar

Murata, K. et al. CD69-null mice protected from arthritis induced with anti-type II collagen antibodies. Int. Immunol. 15, 987992 (2003).

CAS PubMed Article Google Scholar

Capsoni, F. et al. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Res. Ther. 7, 208 (2005).

CAS PubMed PubMed Central Article Google Scholar

Leite Pereira, A. et al. Characterization of phenotypes and functional activities of leukocytes from rheumatoid arthritis patients by mass cytometry. Front. Immunol. 0, 2384 (2019).

Article CAS Google Scholar

Lin, S.-J. et al. Phenotypic and functional characterization of natural killer cells in rheumatoid arthritis-regulation with interleukin-15. Sci. Rep. 2020(10), 18 (2020).

Google Scholar

Schittenhelm, L., Robertson, J., Pratt, A. G., Hilkens, C. M. & Morrison, V. L. Dendritic cell integrin expression patterns regulate inflammation in the rheumatoid arthritis joint. Rheumatology (Oxford) 60, 1533 (2021).

CAS Article Google Scholar

Torsteinsdttir, I., Arvidson, N. G., Hllgren, N. G. & Hkansson, L. Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effect of glucocorticoids. Scand. J. Immunol. 50, 433439 (1999).

PubMed Article Google Scholar

Maldonado, A. et al. Decreased effector memory CD45RA+ CD62L- CD8+ T cells and increased central memory CD45RA- CD62L+ CD8+ T cells in peripheral blood of rheumatoid arthritis patients. Arthritis Res. Ther. 5, R91 (2003).

PubMed PubMed Central Article Google Scholar

Navarro-Hernndez, R. E. et al. Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms. Dis. Markers 26, 119126 (2009).

PubMed PubMed Central Article Google Scholar

Klimiuk, P. A., Fiedorczyk, M., Sierakowski, S. & Chwiecko, J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand. J. Rheumatol. 36, 345350 (2007).

CAS PubMed Article Google Scholar

Klimiuk, P. A., Sierakowski, S., Domyslawska, I. & Chwiecko, J. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 38, 439444 (2009).

CAS PubMed Article Google Scholar

Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492 (2014).

CAS PubMed Article Google Scholar

Wijbrandts, C. A. & Tak, P. P. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin. Proc. 92, 11291143 (2017).

CAS PubMed Article Google Scholar

Schinnerling, K., Rosas, C., Soto, L., Thomas, R. & Aguilln, J. C. Humanized mouse models of rheumatoid arthritis for studies on immunopathogenesis and preclinical testing of cell-based therapies. Front. Immunol. 10, 203 (2019).

CAS PubMed PubMed Central Article Google Scholar

Koboziev, I. et al. Use of humanized mice to study the pathogenesis of autoimmune and inflammatory diseases. Inflamm. Bowel Dis. 21, 16521673 (2015).

PubMed Article Google Scholar

Rothbauer, M. et al. Establishment of a human three-dimensional chip-based chondro-synovial co-culture joint model for reciprocal cross-talk studies in arthritis research. Lab Chip 21, 4128. https://doi.org/10.1101/2021.02.19.431936 (2021).

CAS Article PubMed Google Scholar

Damerau, A. & Gaber, T. Modeling rheumatoid arthritis in vitro: From experimental feasibility to physiological proximity. Int. J. Mol. Sci. 21, 125 (2020).

Google Scholar

Jorgensen, C. & JSimon, M. In vitro human joint models combining advanced 3D Cell culture and cutting-edge 3D bioprinting technologies. Cells 10, 596 (2021).

PubMed PubMed Central Article Google Scholar

Edilova, M. I., Akram, A. & Abdul-Sater, A. A. Innate immunity drives pathogenesis of rheumatoid arthritis. Biomed. J. 44, 172182 (2021).

PubMed Article Google Scholar

Yamin, R. et al. High percentages and activity of synovial fluid NK cells present in patients with advanced stage active rheumatoid arthritis. Sci. Rep. 2019(9), 112 (2019).

Google Scholar

Talbot, J. et al. CCR2 expression in neutrophils plays a critical role in their migration into the joints in rheumatoid arthritis. Arthritis Rheumatol. (Hoboken, NJ) 67, 17511759 (2015).

CAS Article Google Scholar

Vasanthi, P., Nalini, G. & Rajasekhar, G. Status of oxidative stress in rheumatoid arthritis. Int. J. Rheum. Dis. 12, 2933 (2009).

PubMed Article Google Scholar

Adhya, S. et al. Serology and immunoglobulin profile in rheumatoid arthritis. Indian J. Pathol. Microbiol. 41, 4347 (1998).

CAS PubMed Google Scholar

Yang, S., Liu, F., Wang, Q. J., Rosenberg, S. A. & Morgan, R. A. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS One 6, e22560 (2011).

ADS CAS PubMed PubMed Central Article Google Scholar

Ivetic, A., Hoskins Green, H. L. & Hart, S. J. L-selectin: A major regulator of leukocyte adhesion. Migr. Signal. Front. Immunol. 10, 1068 (2019).

CAS Article Google Scholar

Khan, S. Q., Khan, I. & Gupta, V. CD11b activity modulates pathogenesis of lupus nephritis. Front. Med. 0, 52 (2018).

Article Google Scholar

Hassan, W. A., Baraka, E. A. & Fouad, N. A. Clinical significance of soluble programmed death-1(sPD-1) in rheumatoid arthritis patients: Relation to disease activity and functional status. Egypt. Rheumatol. 37, 165169 (2015).

Article Google Scholar

Luo, Q. et al. Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis. Mol. Med. Rep. 17, 32973305 (2018).

CAS PubMed Google Scholar

Liu, Y. et al. Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity. Clin. Immunol. 137, 288295 (2010).

CAS PubMed Article Google Scholar

Wan, B. et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177, 88448850 (2006).

CAS PubMed Article Google Scholar

Flores-Borja, F., Jury, E. C., Mauri, C. & Ehrenstein, M. R. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 105, 1939619401 (2008).

ADS CAS PubMed PubMed Central Article Google Scholar

Gerards, A. H., de Lathouder, S., de Groot, E. R., Dijkmans, B. A. C. & Aarden, L. A. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 42, 11891196 (2003).

CAS PubMed Article Google Scholar

Zamora-Atenza, C. et al. Adalimumab regulates intracellular TNF production in patients with rheumatoid arthritis. Arthritis Res. Ther. 16, R153 (2014).

PubMed PubMed Central Article CAS Google Scholar

Schuerwegh, A. J., Van Offel, J. F., Stevens, W. J., Bridts, C. H. & De Clerck, L. S. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford). 42, 541548 (2003).

CAS PubMed Article Google Scholar

Follow this link:
Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific...

In February, UCI launched the Institute for Precision Health, a campus-wide, interdisciplinary endeavor that merges UCIs powerhouse health sciences, engineering, machine learning, artificial intelligence, clinical genomics and data science capabilities. The objective is to identify, create and deliver the most effective health and wellness strategy for each individual person and, in doing so, confront the linked challenges of health equity and the high cost of care.

IPH will bring a multifaceted, integrated approach to what many call the next great advancement in healthcare. The institute is an ecosystem for collaboration across disciplines that comprises seven areas. Along with co-directing the institute, Leslie Thompson Donald Bren and Chancellors Professor in psychiatry & human behavior and neurobiology & behavior co-leads the precision omics section, which generates and translatesgenomic, proteomic and metabolomic research results into clinical applications.

Thompson is among the earliest trailblazers in pursuing personalized treatment strategies for neurodegenerative diseases. Under her co-direction, IPH pushes for understanding the mechanisms for neurodegenerative and other diseases for which there are currently no treatments available. A long-time Anteater, Thompson earned her masters and Ph.D. from UCI.

Why is the Institute for Precision Health so important to you?

So far, precision medicine approaches have mostly commonly been used to treat cancer. Clinicians can utilize data-driven approaches to determine whether a given drug would be expected to work in a specific individual. Ive dedicated my career to studying neurodegenerative diseases like Huntingtons and ALS. With so many of these diseases, including the more common Alzheimers and Parkinsons disease, there is no treatment available that changes the course of the disease, and so many clinical trials have failed to show benefit to patients. Many researchers think the reason there is so little by way of treatment is because we havent been able to fully understand the diseases in individuals that there is not a one-size-fits-all in disease treatment. We need to have ways of understanding diseases in subgroups of patients that incorporates their genetics, environment and other factors that influence health so that we can define diseases better, understand them better and hopefully treat them better. Thats one aspect of IPH that really motivates me.

The capabilities of Institute for Precision Health might allow for better treatments?

Yes. And more. With the resources of IPH, what we can do has broadened significantly. So not only can we use data to understand these diseases and subgroups of patients better, but we can also develop and use state-of-the art analytic tools such as machine learning and artificial intelligence to distinguish individual disease features and or predict the course of disease. The capabilities of IPH through efforts of clinicians who use AI have enabled establishing a scoring system to inform which COVID-19 patients would be predicted to lead to more severe disease and thus greater medical intervention and optimized patient treatment. A critical aspect of healthcare is to understand the needs of the community as well, which is a major component of IPH. A goal is to utilize the infrastructure being developed through IPH to help clinical trials happen much more rapidly with the right cohort of patients, have new ways to evaluate effectiveness of treatments, engage communities and move into a realm of greater partnership with patients and their communities.

The capacity of UCIs Collaboratory the data center of IPH is key?

Yes. It is extremely challenging to put the various forms of data and information for, say, a given person or a given disease together in one place one platform so that researchers, clinicians and other partners can access and work with the data. With UCIs Collaboratory and our platform provider Syntropy, we can gather not only the de-identified health information that is in the medical record but also relevant genomic or other clinical or research data. The goal is to provide broad benefit to UCI and broad engagement across campus. And really beyond the campus.

Does this feel a little like the launch of the first smart phone, where in the beginning we marveled at the cool features and then, almost immediately, we couldnt imagine life without it?

I think so. And, you know, we had so many of the components here at UCI that have been brought together AI tools being developed across campus and the ability to carry out genomics and other omics, and then the efforts of the Collaboratory and the platforms that can house data. But while components were there, they hadnt yet been integrated into that smart phone, so to speak. Now were putting the components together and continually improving capabilities. Our vision is to provide a systematic approach to accomplish things we have never been able to do previously. Even seemingly small things like, how do you track one patient without any identifiers and all the information thats relevant to that patient and their disease? And so much more.

Youve been a part of groundbreaking research and have had so many professional accomplishments. How exciting is IPH in comparison to what youve already done?

Ive been involved in many very meaningful research projects in my career, but to be perfectly honest, this is huge for me, as I feel it ultimately can help the families that I so passionately care about. I see this as my whole career in human genetics and studying human disease has led up to IPH.

The vision is right, the opportunity is here, and UCIs leadership is so supportive of IPH. There is a growing excitement that, yes, we can do something transformative. So, I hope for big things to come out of IPH. Yes, Im all in.

You mentioned that you believe the work IPH does will benefit people beyond the campus. Can you talk a little bit about that?

I think well see further relationships with industry, with community groups, with other research institutions and clinical entities and most importantly with the patients themselves. We are building something that increases our ability to use and integrate data, and that will be useful to so many people and will enable greater health equity.

Do you have any sort of success timeline in mind?

I think most researchers hesitate to think that way because there have been diseases many of us thought wed have a cure for in 10 years, and 30 years later there isnt even an effective treatment. But, that said, I do think that the great thing with this is that many of the components have already been initiated and are working and we have incredible opportunities to now integrate efforts and diverse sets of data to inform patient health and disease. Im confident that there will be immediate goals that IPH will achieve throughout the next year or two. Then there are longer goals that will take five years or 10 years. And even longer-range goals that will be refined as we go.

Do you believe that even in a year or two patients who get care through UCI will feel the effects of IPH?

Yes, absolutely. Patients are already impacted because of IPHs work with COVID-19. One project involving genomics is to try and pinpoint the diagnosis for patients with a muscle weakness disorder that has defied genetic diagnosis. During this next year, well see if we can find genetic causes of that disorder. And through efforts of the AI groups, there will be development of algorithms to assess effectiveness of tools or treatments recently deployed in the hospital. Those are just a couple examples.

Do you see a day where many diseases are diagnosed quicker and more accurately?

Thats certainly one of our goals. IPH researchers have already developed an AI tool to diagnose stroke much more quickly compared to more standard methods. I suspect IPH will be working on many more tools that function in similar ways.

What does UCI bring to the table that maybe some other institutions dont?

One big strength is the support from Chancellor Howard Gillman and other campus leaders. [Vice Chancellor of Health Affairs] Steve Goldstein has led the charge for this institute to become a reality. Also, the fact that we have so much AI, machine learning and artificial intelligence expertise across UCI along with many acclaimed clinicians and medical researchers. Having an academic medical center certainly presents opportunities that researchers elsewhere might not have where they may have great AI expertise but without a medical center. We also perhaps have a unique focus health equity with existing relationships with the community. So, we are distinctive in the fact that we have all the pieces here. UCI is also a uniquely collaborative and nimble institution. We come together and make things happen quickly at UCI. Thats a characteristic of this university that Ive seen play out during my whole career here.

Will there be opportunities to study Orange County to see, as a community, what kind of impact IPH has?

IPH is engaged in this already, and it is a major goal moving forward.

And the way youre able to use data is special?

Yes. Quite often researchers have pulled information from the medical records that is structured data, that has an important role in research that has been facilitated at UCI through efforts of the Collaboratory. However, one of the things that is unusual about the platform is that there will be ways to capture all the structured and unstructured data. This is a big deal.

Everything needs funding, though. Whats happening in that regard?

Yes, great question. Certainly, one of the biggest challenges for any endeavor is raising money. Through support by UCI, we have the funds to launch IPH efforts, but there will need to be extensive fundraising and plenty of grant writing. Philanthropy will be integral to our success and visionaries to relay the excitement about our mission.

If you want to learn more about supporting this or other activities at UCI, please visit the Brilliant Future website athttps://brilliantfuture.uci.edu. Publicly launched on October 4, 2019, the Brilliant Future campaign aims to raise awareness and support for UCI. By engaging 75,000 alumni and garnering $2 billion in philanthropic investment, UCI seeks to reach new heights of excellence instudent success,health and wellness, research and more. UCI Health Affairs plays a vital role in the success of the campaign. Learn more by visitinghttps://brilliantfuture.uci.edu/uci-health-affairs/.

About UCI Institute for Precision Health: Founded in February 2022, the Institute for Precision Health (IPH) is a multifaceted, integrated ecosystem for collaboration that maximizes the collective knowledge of patient data sets and the power of computer algorithms, predictive modeling and AI. IPH marries UCIs powerhouse health sciences, engineering, machine learning, artificial intelligence, clinical genomics and data science capabilities to deliver the most effective health and wellness strategy for each individual person and, in doing so, confronts the linked challenges of health equity and the high cost of care. IPH is part of UCI Health Affairs, and is co-directed by Tom Andriola, vice chancellor for information, technology and data, and Leslie Thompson, Donald Bren Professor of psychiatry & human behavior and neurobiology & behavior. IPH is a comprised of seven areas: SMART(statistics, machine learning-artificial intelligence), A2IR(applied artificial intelligence research), A3(applied analytics and artificial intelligence), Precision Omics(fosters translation of genomic, proteomic, and metabolomic research findings into clinical applications), Collaboratory for Health & Wellness(providestheecosystem that fosters collaboration across disciplines through the integration of health-related data sources), Deployable Equity(engagescommunity stakeholders and health-equitygroupsto create solutionsthat narrow the disparities gap in the health and wellbeing of underserved and at-risk populations.) and Education and Training (brings data-centric education to students and healthcare practitioners so they can practice at the top of their licenses).

Originally posted here:
Precision health perspectives - UCI News

Strategic partnership leveraging FidoCure's precision medicine platform advances joint vision for providing personalized, accessible veterinary cancer care

AUSTIN, Texas and PALO ALTO, Calif. (PRWEB) July 15, 2022

Thrive Pet Healthcare, a national veterinary hospital network, and https://www.fidocure.com/FidoCure, the leading pet precision health company, today announced a strategic partnership to provide personalized, accessible veterinary cancer care. Thrive Pet Healthcare's nationwide network of over 350 veterinary care clinics will now have access to FidoCure's cutting edge precision medicine platform and unparalleled algorithmic driven diagnostics. By joining forces, these two patient centric companies are poised to deliver groundbreaking pet specialty cancer care at scale and help improve outcomes in pets with cancer.

With roughly six million new cancer diagnoses in dogs each year, approximately one in three dogs will develop cancer during their lifetime. The FidoCure precision medicine platform, developed to address the vast unmet need for better canine cancer care, uses genomic-guided DNA testing to identify genetic mutations that can cause cancer in dogs and matches them to individualized treatment with targeted therapies.

"We are thrilled to partner with FidoCure to offer ground-breaking precision cancer treatment to pet patients in our communities," said Thrive's Chief Medical Officer, Dr. Scott Schatzberg. "Through this powerful partnership, we reinforce our belief in nurturing the animal-human bond and providing exceptional pet healthcare at every stage of a pet's life. Every cancer case is unique, and now a personalized course of treatment is available to every patient within our nationwide network so that they can thrive."

Approximately 3,000 dogs diagnosed with cancer have used the FidoCure Next Generation DNA Sequencing Test, resulting in the largest proprietary canine cancer dataset in the world. Sharing outcomes data, an additional element of this partnership, will significantly expand this dataset. Since humans and dogs are both vulnerable to similar genetic mutations that may cause cancer, the growth of this dataset may help not only advance canine oncology research, but research for humans as well.

"We are delighted to be collaborating with one of the world's most trusted, innovative, and connected pet healthcare networks. This partnership between FidoCure and Thrive Pet Healthcare means that more pet parents, working with Thrive's leading specialty clinicians, will have streamlined access to this cutting-edge cancer care platform," said Christina K. Lopes, co-founder and CEO of FidoCure.

"It is no secret that wide-scale access to veterinary oncology is sorely needed in the veterinary world. This partnership with FidoCure will enable Thrive Pet Healthcare clinicians across the country to better fulfill our mission of providing comprehensive pet care at every stage of life. As a veterinary oncologist, I'm incredibly excited we can more broadly deliver precision medicine to dogs with cancer. It is essential that the scientific advancements available to humans be made available to pets as well, and now we're doing just that with this partnership with FidoCure," said Dr. Mona Rosenberg, Thrive's National Specialty Director of Oncology and Director of Innovation in Clinical Oncology.

About Thrive Pet HealthcareThrive Pet Healthcare is a leading veterinary service network that uniquely delivers a continuum of care to pet families and services to veterinary hospitals. With an industry-first membership program and over 350 acute, primary, and specialty providers, Thrive Pet Healthcare offers personalized, accessible care through every stage of a pet's life and health. The veterinarian-founded organization provides premier benefits for practice staff while elevating privately held veterinary hospitals with innovative service and technology solutions. By focusing on the needs and aspirations of veterinary care providers, Thrive Pet Healthcare is supporting the wellbeing of the industry and raising the national bar for veterinary excellence. To learn more about Thrive Pet Healthcare, please visit http://www.thrivepetcare.com.

About FidoCureFidoCure is the first to bring the latest advances in human oncology - individualized, precision medicine - to dogs with cancer. We are a mission driven company that delivers the most sophisticated diagnostics and creates a tailored treatment plan for each dog. Our flagship product, FidoCure Next Generation DNA Sequencing Test, leverages technologies and therapies approved for human use, with additional data specific to canine cancer. With FidoCure, dogs with cancer receive access to the latest scientific advances in cancer care, from tests to treatment. FidoCure is backed by premier biotech investors including Polaris Ventures, A16Z, YCombinator and Global Brain. Learn more at fidocure.com.

For the original version on PRWeb visit: https://www.prweb.com/releases/2022/MM/prweb18751199.htm

Continued here:
Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga

DUBLIN--(BUSINESS WIRE)--The "Global Compound Management Market Size, Share & Trends Analysis Report by Type (Products, Service), by Sample Type (Chemical Compounds, Bio Samples), by Application, by End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global compound management market size is expected to reach USD 1.49 billion by the end of 2030, expanding at a CAGR of 15.6%.

Growing biopharmaceutical industry and biobanking sector is fueling the market growth. The growth of translational research and personalized medicine is driving the market.

Efficient compound management is tremendously important for the success of drug discovery, where traceability, reliability, speed, and throughput are fundamental. Maintaining samples at the precise temperature, under nitrogen or dry air to prevent fluctuations of stock concentrations, and in a dark environment to avoid photodegradation, can help ensure consistency and longevity of samples.

Compounds of high integrity lead to reliable results while locating drug candidates. Moreover, the collection, storage, and distribution of human biological samples support the development of the R&D industry. In addition, it aids to understand the mechanisms of diseases as well as supports the trend to provide personalized medicines.

Automated storage systems eliminate or reduce the risks and provide reliable and correct environmental conditions to protect samples from precipitation or degradation. A management system like Verso tracks sample data, including location and type, which enables the quick and easy finding of the sample. The fully automated systems improve the process of drug discovery by eliminating error-prone and time-consuming tasks.

North America dominated the market in 2018 owing to a strong base of biotechnology and pharmaceutical companies in the region. These companies are involved in drug discovery activities, which, in turn, led to the growth of the market in the region. The Asia Pacific market is anticipated to grow fast over the forecast period. This is attributed to ongoing studies in private-public collaborations, drug discovery, and government initiatives in the region.

Compound Management Market Report Highlights

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Competitive Insights

Chapter 3. Compound Management Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Industry Value Chain Analysis

3.3.1. Reimbursement framework

3.4. Market Dynamics

3.4.1. Market driver analysis

3.4.1.1. Growing Drug Research Activities

3.4.1.2. Rising demand for outsourcing compound management services

3.4.1.3. High disease prevalence

3.4.1.4. Expansion of Pharma & Biopharma Research in Emerging Markets

3.4.2. Market restraint analysis

3.4.2.1. Large Capital Investments Required to Establish Compound Management Facilities

3.4.2.2. Quality issues related to compound management by the outsourcing provider

3.5. Compound Management Market Analysis Tools

3.5.1. Industry Analysis-Porter's

3.5.2. PESTEL Analysis

3.5.3. Major Deals & Strategic Alliances Analysis

3.5.4. COVID-19 Impact Analysis

Chapter 4. Compound Management Market: Type Estimates & Trend Analysis

Chapter 5. Compound Management Market: Sample Type Estimates & Trend Analysis

Chapter 6. Compound Management Market: Application Estimates & Trend Analysis

Chapter 7. Compound Management Market: End-Use Estimates & Trend Analysis

Chapter 8. Compound Management Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Profiles

For more information about this report visit https://www.researchandmarkets.com/r/r8bcjv

Go here to read the rest:
The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire

Myriad Genetics, Inc.

Study showed PGx testing helps clinicians prescribe fewer medications with gene-drug interactions

SALT LAKE CITY, July 12, 2022 (GLOBE NEWSWIRE) -- Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight Psychotropic test results from Myriad Genetics, Inc. (NASDAQ: MYGN), according to a new nationwide study of nearly 2,000 veterans conducted by the U.S. Department of Veterans Affairs (VA).

The PRIME Care (Precision Medicine in Mental Health Care) study is the largest pharmacogenomic (PGx) randomized controlled trial (RCT) ever conducted in mental health. Results of the study were published in the July 2022 issue of the Journal of the American Medical Association (JAMA). The VA independently conducted and funded the study. Myriad Genetics provided the GeneSight tests for the study.

The number of veterans suffering from depression is a serious mental health issue. The PRIME Care study showed that veterans are more likely to achieve depression remission when GeneSight test results are available to inform medication treatment, said Paul J. Diaz, president and CEO, Myriad Genetics. We thank the VA and the investigators for conducting this important research. The results demonstrate how veterans may be helped by clinicians who provide personalized medication treatment and how such treatment can help make a positive impact on their lives, their families lives, and their communities.

In the PRIME Care study, 1,944 veteran patients with MDD received the GeneSight Psychotropic test and were randomized to receive results immediately (pharmacogenomic guided group) or after 24 weeks (usual care group). The study met its objective by achieving statistically significant results on both co-primary endpoints.

One co-primary endpoint showed that over 24 weeks, the pharmacogenomic guided group had a 28% greater likelihood (odds ratio = 1.28, 95% confidence interval 1.05-1.57, p=0.02) of achieving remission from MDD symptoms (defined as a score of five or less on the PHQ-9 depression symptom questionnaire). There were no identified harms from receiving GeneSight testing in the study.

Story continues

The VA PRIME Care Study further reinforces the body of evidence supporting the clinical utility of the GeneSight test as an important tool to inform medication selection in MDD treatment. The study showed a meaningful increase in remission rates for patients whose providers had access to GeneSight test results, said Jay Elliott, vice president, medical affairs of mental health, Myriad Genetics. Remission represents a reduction in symptoms and return to normal or near-normal function, which is considered the optimal treatment goal for both providers and patients.

Another co-primary endpoint showed that patients in the usual care group were approximately two-fold more likely (odds ratio = 2.08, 95% confidence interval 1.52-2.84, p=0.005) to be prescribed medications with substantial predicted gene-drug interactions compared to the pharmacogenomic guided group in the first 30 days after randomization.

Among patients with MDD, provision of pharmacogenomic testing for drug-gene interactions reduced prescription of medications with predicted drug-gene interactions compared with usual care, according to the JAMA publication of the PRIME Care study.

Major Depressive Disorder is one of the most common conditions associated with military service and combat exposure, increases suicide risk, and worsens the course of common medical conditions, making it a leading cause of disability and mortality, according to the VA PRIME Care study website. In fact, the VA estimates that one in eight to 10 veterans has major depression, requiring treatment with psychotherapy and/or antidepressants.1

_______________1 U.S. Department of Veterans Affairs. https://www.research.va.gov/topics/depression.cfm

About the PRIME Care Study

The 24-week PRIME Care study was conducted among 1,944 Veterans who were diagnosed with Major Depressive Disorder at more than 20 VA Medical Centers around the country. The study focused on whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat MDD and whether use of the genetic test results improves patient outcomes. Results were calculated at weeks four, eight, 12, 18, and 24.

The study was a two-arm, parallel-groups comparison of patient/provider dyads randomly assigned to receive the results of the GeneSight test at the time the planned treatment is initiated (intervention group) OR results returned after 24 weeks of treatment as usual (delayed results group).

The study incorporated a widely used depression questionnaire, the PHQ-9, to assess severity of depression symptoms. A score of five or less indicates remission of depression symptoms. Patients were required to have a score of nine or more on the PHQ-9 to enroll in the PRIME Care study.

About the GeneSight Test

The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patients genes may impact how they metabolize and/or respond to certain psychiatric medications. It is designed to provide information that may help avoid the trial-and-error process that often takes place when patients are prescribed certain mental health medications. Tens of thousands of clinicians have ordered the GeneSight test for more than 1.5 million patients in order to receive genetic information that is unique to each patient. GeneSight can be easily ordered by psychiatrists, general practitioners, nurse practitioners and other prescribers via a secure portal. The test can be administered in a home-based kit or a providers office using a simple cheek swab. GeneSight test results are typically provided in two days and supplement other information considered by a clinician as part of a comprehensive medical assessment. Learn more at GeneSight.com.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the Worlds Most Innovative Companies for 2022. For more information, visit http://www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. 2022 Myriad Genetics, Inc. All rights reserved.

Media Contact:Sharvari Dayal(330)-354-7150sharvari.dayal@myriad.com

Investor Contact:Foster Harris(919) 998-8379foster.harris@myriad.com

Continued here:
Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo...

DUBLIN--(BUSINESS WIRE)--The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022" report has been added to ResearchAndMarkets.com's offering.

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated.

iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Other applications of iPSCs include their use as research products, as well as their integration into 3D bioprinting, tissue engineering, and clean meat production. Technology allowing for the mass-production and differentiation of iPSCs in industrial-scale bioreactors is also advancing at breakneck speed.

iPSC Derived Clinical Trials

The first clinical trial using iPSCs started in 2008, and today, that number has surged worldwide. Most of the current clinical trials do not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest.

The therapeutic applications of induced pluripotent stem cells (iPSCs) have also surged in recent years. Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been used within a rapidly growing number of preclinical studies, physician-led studies, and formal clinical trials worldwide.

Key Topics Covered:

1. Report Overview

2. Introduction

3. Current Status of iPSC Industry

3.1 Progress Made in Autologous Cell Therapy Using iPSCs

3.2 Manufacturing Timeline for Autologous iPSC-Derived Cell Products

3.3 Cost of iPSC Production

3.4 Automation in iPSC Production

3.5 Allogeneic iPSCs Gaining Momentum

3.6 Share of iPSC-Based Research Within the Overall Stem Cell Industry

3.7 Major Focus Areas of iPSC Companies

3.8 Commercially Available iPSC-Derived Cell Types

3.9 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays

3.10 Currently Available iPSC Technologies

4. History of Induced Pluripotent Stem Cells (iPSCs)

5. Research Publications on iPSCs

6. iPSC: Patent Landscape Analysis

6.1 Legal Status of iPSC Patents

6.2 Patents by Assignee Organization Type

6.3 Ownership of Patent Families by Assignee Type

6.4 Top Inventors of iPSC Patents

6.5 Top Ten iPSC Inventors

6.6 Most Cited Five iPSC Patents

6.7 Leading Patent Filing Jurisdictions

6.8 Number of Patent Families by Year of Filing

6.9 Patents Representing Different Disorders

6.10 iPSC Patents on Preparation Technologies

6.11 Patents on Cell Types Differentiated from iPSCs

6.12 Patent Application Trends Disease-Specific Technologies

7. iPSC: Clinical Trial Landscape

7.1 Literature and Database Search

7.2 Number of iPSC Clinical Trials by Year

7.3 iPSC Study Designs

7.4 iPSC-Based Clinical Trials With Commercialization Potential

8. Research Funding for iPSCs

8.1 Value of NIH Funding for iPSC Research

8.2 Partial List of NIH Funded iPSC Research Projects in 2022

9. M&A, Collaborations & Funding Activities in iPSC Sector

10. Generation of Induced Pluripotent Stem Cells: An Overview

10.1 Reprogramming Factors

10.2 Integrating iPSC Delivery Methods

10.3 Non-Integrative Delivery Systems

10.4 Comparison of Delivery Methods for Generating iPSCs

10.5 Genome Editing Technologies in iPSC Generation

11. Human iPSC Banking

11.1 Cell Sources for iPSC Banking

11.2 Reprogramming Methods Used in iPSC Banking

11.3 Factors Used in Reprogramming in Different Banks

11.4 Workflow in iPSC Banks

11.5 Existing iPSC Banks

12. Biomedical Applications of iPSCs

12.1 iPSCs in Basic Research

12.2 iPSCs in Drug Discovery

12.3 iPSCs in Toxicology Studies

12.4 iPSCs in Disease Modeling

12.5 iPSCs in Cell-Based Therapies

12.6 Other Novel Applications of iPSCs

12.7 iPSCs in Animal Conservation

13. Market Overview

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/mg6l5h

Read more:
Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -...

MarketsandMarkets Research Pvt. Ltd.

Chicago, July 15, 2022 (GLOBE NEWSWIRE) -- According to the new market research report Research Antibodies and Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End User (Pharma, Biotech, CROs) - Global forecast to 2027, published by MarketsandMarkets, the global Research Antibodies and Reagents Market are projected to reach USD 16.1 billion by 2027 from USD 11.6 billion in 2022, at a CAGR of 6.7% during the forecast period.

Browse in-depth TOC on Research Antibodies Market and Research Reagents Market244 Tables46 Figures285 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793

The Factors responsible for driving the market are, increasing growth in proteomics and genomics research, growing demand for high-quality antibodies for research reproducibility, and increasing R&D investments in the life sciences industry.

The antibodies segment is expected to grow at the highest CAGR during the forecast period

On the basis of product, the research antibodies and reagents market are segmented into reagents and antibodies. The antibodies segment is expected to grow at highest CAGR in forecast periods (2022-2027). Factors such as antibodies use for research offer high specificity and selectivity and are used ubiquitously in biochemical and medical research for protein-target identification, regulatory characterization, and discovery, are driving the market.

The primary antibodies segment is accounts for the largest share of the research antibodies and reagents market

On the basis of type, the research reagents market are segmented into primary antibodies and secondary antibodies. In 2021, the primary antibodies segment held the largest share of the global research antibodies market. This segment is witnessing a strong growth due to the use of these antibodies in numerous types of assay formats. Their accuracy in biomarker detection and high specificity and sensitivity are also driving the market.

Story continues

The media & sera reagent is expected to account for the largest share of the market, by type, in 2021

On the Basis of type, the research antibodies and reagents market are segmented into media &sera, stains & dyes, fixatives, buffers, solvents, enzymes, probes, and other reagents. In 2021, the media & sera reagent segment held the largest share of the global research antibodies market. Factors such as use of these components in all types of assays, cell cultures, and techniques is driving the market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=94212793

The western blotting segment is expected to account for the largest share of the market, by technology, in 2021

On the basis of technology, the research antibodies and reagents market are segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. The Western blotting segment is expected to grow at highest CAGR in forecast periods (2022-2027). Factors such as the high adoption of technique in proteomic and genomic research. The results achieved are unique, easy to interpret, and unambiguous, making it suited for evaluating levels of protein expression in cells, protein purification, and comparing the expression of a target protein from various tissues.

The drug development applications segment is expected to grow at the highest CAGR during the forecast period

On the basis of application, the research antibodies and reagents market are segmented into proteomics, drug development and Genomics. The drug development segment is expected to grow at highest CAGR in forecast periods (2022-2027). Factors such increasing demand for personalized medicine and government funding & initiatives in the sector are the key market drivers for this segment.

The pharmaceutical & biotechnology segment is expected to grow at the highest CAGR during the forecast period

On the basis of end user, the research antibodies and reagents market are segmented into the pharmaceutical & biotechnology companies, academic & research institutions, and Contract Research Organizations. Factors such as the growth of this segment is due to antibodies provide a gold standard for the detection of a biomolecule or a pathway and are even capable of detecting specific changes in potential drug targets. Moreover, highly specific reagents are used to measure pharmacokinetic parameters in the preclinical and clinical development of biological drugs are the key market drivers for this segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=94212793

The APAC market is expected to grow at the highest CAGR during the forecast period

The Asia Pacific research reagents market is expected to grow at the highest CAGR from 2022 to 2027. Factors such as increasing proteomics and genomics research and growing research funding, increasing investments by pharmaceutical and biotechnology companies are driving the market.

Prominent market players in Research Antibodies Market and Research Reagents Market are:

Thermo Fisher Scientific, Inc. (US),

Merck KGaA (Germany),

Abcam plc (UK),

Becton, Dickinson, and Company (US),

Bio-Rad Laboratories (US),

Cell Signaling Technology (US),

F. Hoffmann-La Roche (Switzerland),

Danaher Corporation (US),

Agilent Technologies (US),

PerkinElmer (US),

Lonza (Switzerland),

GenScript (China), and

BioLegend (US).

Browse Adjacent Markets:Biotechnology Market Research Reports & Consulting

Browse Related Reports:

Flow Cytometry Market by Technology (Cell-based, Bead-based), Product (Analyzer, Sorter, Reagents, Consumables, Software), End user (Academia, Research Labs, Hospitals, Clinical Laboratories, Pharma-Biotech Cos), Application - Global Forecasts to 2025https://www.marketsandmarkets.com/Market-Reports/flow-cytometry-market-65374584.html

Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023https://www.marketsandmarkets.com/Market-Reports/custom-antibody-market-164328301.html

Continued here:
Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance

Custom Antibody Market Is Expected To Reach USD 742.27 Million By 2029 At A CAGR Of 10.3 percent.

Maximize Market Research has published a report on theGlobal Custom Antibody Market that provides a detailed analysis for the forecast period of 2022 to 2029.

Custom Antibody Market Scope:

The report provides comprehensive market insights for industry stakeholders, including an explanation of complicated market data in simple language, the industrys history and present situation, as well as expected market size and trends. The research investigates all industry categories, with an emphasis on key companies such as market leaders, followers, and new entrants. The paper includes a full PESTLE analysis for each country. A thorough picture of the competitive landscape of major competitors in the Custom Antibody market by goods and services, revenue, financial situation, portfolio, growth plans, and geographical presence makes the study an investors guide.

Request For Free Sample @https://www.maximizemarketresearch.com/request-sample/34046

Custom Antibody Market Overview:

To accommodate any host needs, customised antibodies can be produced in a mouse, rat, or hamster. Companies offer a wide variety of antibodies based on the needs of the researcher. Polyclonal and monoclonal antibodies, recombinant monoclonal antibodies, hybridoma antibodies, polyclonal recombinant antibodies, and others are available in the market as customised antibodies. For all types and stages of antibody manufacturing, including peptide design, synthesis, carrier protein conjugation, animal immunisation, serum collection, hybridoma fusion, and final antibody purification, businesses are now providing full support services.

Custom Antibody MarketDynamics:

The strong need for research, expanding government assistance, changing illness profiles, developing public-private collaborations, and rising funding activities are all contributing to the expansion of the bespoke antibody market. These aspects also help biotechnology perform better overall. However, depending on the animals used to produce them, the generation of monoclonal and polyclonal antibodies varies. The cost is also influenced by the packages of customised antibodies required for various applications that are provided by various providers, which restricts market expansion.

A key area of research in the healthcare sector, personalised medicine has now permeated mainstream clinical practise and is revolutionising how many diseases are diagnosed, categorised, and treated. These developments are especially noticeable in oncology. The number of personalised medicine medications, therapies, and diagnostic products has grown since 2006, and this trend is anticipated to continue in the upcoming years, according to the Personalized Medicine Coalition study (2020). Additionally, over the past five years, biopharmaceutical companies have almost doubled their R&D expenditures in personalised medicine; over the following five years, this expenditure is predicted to rise by 33 percent. Over the past few years, there has been a surge in the need for protein treatments, such as hormones, vaccines, monoclonal antibodies, blood factors, and therapeutic enzymes

Custom Antibody MarketRegional Insights:

A key area of research in the healthcare sector, personalised medicine has now permeated mainstream clinical practise and is revolutionising how many diseases are diagnosed, categorised, and treated. These developments are especially noticeable in oncology. The number of personalised medicine medications, therapies, and diagnostic products has grown since 2006, and this trend is anticipated to continue in the upcoming years, according to the Personalized Medicine Coalition study (2020). Additionally, over the past five years, biopharmaceutical companies have almost doubled their R&D expenditures in personalised medicine; over the following five years, this expenditure is predicted to rise by 35 percent. Over the past few years, there has been a surge in the need for protein treatments, such as hormones, vaccines, monoclonal antibodies, blood factors, and therapeutic enzymes.

Custom Antibody MarketSegmentation:

By Services:

By Type:

By Source:

By Research area:

By End-Users:

Custom Antibody Market Key Competitors:

To Get A Copy Of The Sample of the Custom Antibody Market, Click Here @https://www.maximizemarketresearch.com/market-report/global-custom-antibody-market/34046/

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[emailprotected]

Here is the original post:
Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal

People with extreme nearsightedness, or myopia, may experience myopic macular degeneration (MMD). This condition can lead to a gradual decrease in central vision.

In people with myopia, the distance between the front and back of each eye is greater than average. This increased eyeball size makes it harder to focus on objects in the distance. Some people with this condition may be at greater risk of developing other eye conditions.

This article will review all there is to know about MMD, from signs and symptoms to the latest research.

MMD, also called degenerative myopia, is the leading cause of legal blindness.

The macula is a tiny region located in the center of the retina. When the retina stretches in people with myopia, it can cause the cells in the macula to degenerate.

If damage occurs to cells in the macula, individuals may experience a blind spot in their central vision. The resulting condition is called MMD.

The causes of MMD vary between individuals.

Excessive stretching can change the arrangement of photoreceptors within the eye. This can impact vision even before degeneration begins.

Changes in certain proteins can also occur as a result of eyeball elongation. Atypical collagen proteins, for example, can lead to a weaker eye structure and cause retinal degeneration.

Additionally, researchers believe that inflammatory conditions may contribute to MMD. Chronic inflammation in the eye tissue may further alter eye structure and function.

Although research links macular degeneration and myopia, not all people with myopia will experience macular degeneration.

During the early stages of MMD, people may experience few, if any, symptoms. A blurry spot in the central vision may eventually appear and worsen with time.

Other common symptoms may include:

People who experience unexpected vision changes should consult an eye specialist.

Changes in central vision, gray or blurry spots, or having trouble reading and recognizing people may all indicate MMD.

A specialist will perform a thorough exam and diagnostic tests to determine whether a persons symptoms indicate MMD. They can then discuss the individuals outlook and treatment options.

People with MMD may experience complications. For example, damage to the retina or scarring in the macula tissue may occur. MMD can lead to blindness in severe cases.

Individuals who receive a diagnosis of MMD should consult with a doctor to prevent any potential complications.

Each case of MMD is unique, and only a medical professional can provide an accurate assessment.

Older individuals and people with very severe myopia have a higher chance of developing MMD.

Research from 2022 suggests that genetics and a persons environment can play a role in the development and severity of myopia. A family history of myopia increases an individuals risk of nearsightedness. A person can also inherit changes to genes involved in eyesight.

Additionally, research indicates that spending more time outdoors helps prevent myopia and that modern, urban lifestyles may put individuals at risk of developing myopia and MMD.

There is currently no single cure for MMD. However, several different treatment options may help prevent vision loss among those who develop this condition.

People with MMD usually develop new blood vessels under the retina. These blood vessels can leak and worsen the effects of MMD. One of the most common treatments involves anti-vascular endothelial growth factor (anti-VEGF) injections. Anti-VEGF drugs may reduce new blood vessel growth, improve vision, and slow macular thickening.

Research also indicates that photodynamic therapy may help treat MMD. Read more about laser therapy for macular degeneration here.

A possible surgical procedure is posterior scleral reinforcement (PSR). The main objective of PSR is to slow down axial elongation, which occurs with myopia.

No one treatment protocol is right for everyone. Individuals with MMD should speak with a medical professional to explore the best treatment options for their unique case.

Managing myopia early in life can help reduce the risk of developing MMD. Possible ways to do this include avoiding exposure to screens and emphasizing time spent outdoors.

Other treatments, such as atropine eye drops, can also help decrease myopia progression in children.

In mild cases of myopia, eyeglasses or contact lenses can improve eyesight. People with more severe myopia may elect to have surgery.

Consistent, thorough eye exams can help detect vision changes early. Eye specialists recommend people with severe myopia and MMD have eye exams every year or more frequently if needed.

During an eye exam, a specialist can ensure that the eyes function correctly. They can also monitor any vision changes that develop gradually.

Individuals with severe myopia may be at greater risk for MMD. This condition can lead to vision changes or, in extreme cases, blindness.

Managing myopia early in life can help reduce the risk of developing MMD. Routine eye examinations with a specialist can also help detect vision problems in their earliest stages.

People who experience myopia should work with a medical professional to manage and monitor their condition over time. Consistent medical support can help manage myopia and reduce the long-term effects of MMD.

Read the rest here:

Myopic macular degeneration: What it is, and more - Medical News Today

Courtesy of Smith Collection Gado/Getty Images

Roche has had a good week, sharing positive two-year data from Genentech's study on Vabysmo for age-related macular degeneration and eight-year data in its trial for combination therapy for HER2-positive early breast cancer.

2-Year Data On Vabysmo Demonstrates Reliability & Safety

Genentech, a part of the Roche Group, shared positive two years' worth of data from its ongoing LUCERNE and TENAYA trials, which are looking into Vabysmo's (faricimab-svoa) long-term safety, efficacy and durability in wet or neovascular AMD.

In both the TENAYA and LUCERNE studies, over 60% of the participants were able to be treated every four months, up 15% from where they were in the first year. Almost 80% were able to treat at least every three months. No new safety signals came up, and the drug continued to be well tolerated and demonstrate a favorable risk profile.

"These longer-term results reinforce confidence in Vabysmo and support its continued use in people with wet AMD. With the potential to require fewer injections over time, Vabysmo continues to represent an important step forward for people with vision-threatening retinal conditions, and these data exemplify our commitment to redefining standards of care and reducing treatment burden," Levi Garraway, M.D., Ph.D., chief medical officer and head of global product development at Genentech, said in a statement.

The disorder, a leading cause of vision loss, affects around 1.1 million people in the United States alone. Treatment usually involves eye injections administered every one or two months. Vabysmo is evaluated for its potential to reduce the frequency of injections.

Vabysmo is the first bispecific antibody for the eye and the only injectable eye medicine approved by the U.S. Food and Drug Administration. It is currently under review by the European Medicines Agency and other regulatory agencies worldwide.

Combination Breast Cancer Therapy Delivers Positive 8-Year Data

Meanwhile, Roche announced positive eight-year data from its long-term evaluation of Perjeta (pertuzumab) combined with Herceptin (trastuzumab) and chemotherapy (Perjeta-based) in HER2-positive early breast cancer, versus Herceptin, chemotherapy and a placebo.

Results at 8.4 years, with a median follow-up of 101 months, showed that patients with lymph node-positive disease saw a 28% reduction in the risk of recurrence or death. The combination's safety profile also remained consistent with previous trials. There were fewer deaths at 168 versus 202 in the placebo group, and around 88.4% of those who received the treatment post-surgery had remained disease-free compared to the 85.8% of the placebo takers.

"The eight-year APHINITY results show the great progress made in treating this aggressive form of early breast cancer. HER2-positive breast cancers are more likely than other subtypes to recur following surgery, so targeted treatment is critical to provide the best chance for a cure," Garraway said, who is also Roches chief medical officer and head of global product development.

Details were presented at the European Society for Medical Oncology (ESMO) Virtual Plenary.

Read more here:

Roche Wraps Week with a Bang, Touting Long-Term Breast Cancer, AMD Data - BioSpace

Do you see small mosquitoes and flies in front of your eyes, but you cannot drive them away no matter how you try? This is commonly known as eye floater syndrome or eye floaters and also known as muscae volitantes. Especially when looking at a white wall or the blue sky, floaters, which are dark shadows, are quite obvious. Some of these shadows are not shaped like bugs, but rather spots, filaments, and rings. In severe cases, the condition will affect the vision, causing inconvenience in daily life. In some cases, eye floaters may be a sign of serious eye disease.

What are the symptoms of eye floaters, and under what circumstances is there risk of blindness? What are the causes of eye floaters and treatments? We will explain below with infographics.

Eye floaters usually appear as follows:

Eye floaters have subjective symptoms, and the condition is closely associated with the vitreous humor in the eye. In medical terms, it is also known as vitreous clouding or vitreous degeneration.

What is vitreous humor (aka. vitreous body)?

It is a colorless, transparent colloid inside the eye, covered with a vitreous membrane. It is located between the lens and the retina and fills four-fifths of the eye, and its role is to support the retina, so that it can fittingly line the back wall of the eye.

The formation of eye floaters is generally due to the natural aging process of the vitreous humor, which liquefies and condenses, thus producing some cellular debris and adhesives. When these floating impurities in the vitreous humor are projected on the retina by light, the patient will see insects that cannot be driven away.

Most eye floaters are physiological and develop after the age of 40 due to the natural aging of the eyeball.

However, some can also be caused by eye diseases. Trauma to the eye, intraocular inflammation, retinal detachment, and vitreous hemorrhage are all pathological causes of muscae volitantes.

In ancient times, Chinese medicine practitioners called eye floaters fluttering and drifting cloud-like dark shadows or dark flowers and fly wings.

According to traditional Chinese medicine, the causes of the eye floater syndrome are related to the visceral disorders of the body, mainly damp turbidity, liver-kidney deficiency, and the deficiency of qi and blood. This can still be observed today, as many of the other symptoms of these deficiencies may accompany the appearance of floaters.

Damp turbidity: When the bodys dampness becomes too heavy, infringing on the vitreous humor in the eyes, the patient may also experience dizziness, chest congestion, poor digestion, and other symptoms. If you observe the patients tongue, you may see the phenomenon of thick and greasy tongue coating.

Liver-kidney deficiency: The deficiency of essence and blood in the liver and kidney will impede the supplying of nutrients to the eyes, thus causing cloudiness in the vitreous humor. Such patients may also experience tinnitus and back pain.

Qi and blood deficiency: Due to prolonged illness or blood loss, qi and blood deficiency may occur, and as the eyeballs cannot get sufficient nourishment from the blood, eye floaters may form. The patient may also experience dry eyes and photophobia. These patients are prone to having a pallid complexion and experiencing dizziness and palpitations.

Traditional Chinese medicine has a well-known prescription for eye treatment called water honeyed pill (lycii and chrysanthemi and rehmanniae bolus), which can also improve eye floater symptoms.

It includes rehmanniae, which can nourish the liver and kidneys, and goji berries and chrysanthemums, which can help improve eyesight. However, it is not suitable for patients with a cold or flu. If a patient has chronic diseases, such as high blood pressure, heart diseases, liver diseases, and diabetes, the medication should be taken under the instruction of a doctor.

When many patients first discover that they have eye floaters, they are particularly worried, fearing it is a symptom of a major or looming problem. In fact, eye floaters formed due to age are a normal phenomenon, and these people dont need to worry much.

However, the following conditions can cause serious eye floater syndrome, and even have the risk of blindness, so we must pay special attention to them:

Retinal detachment: The vitreous humor supports the retina at the back of the eyeball and is attached to the retina. If the vitreous liquefaction is too severe, the vitreous humor will gradually separate from the retina. And in the separation process, retinal tears and breaks develop when the vitreous pulls on the retina; if the liquefied vitreous humor pours in through the holes, it will cause retinal detachment.

When the vitreous humor pulls on the retina, flashes will appear in the vision; if the vitreous humor and retina are detached, flashes may occur frequently. If the retinal blood vessels are torn, blood will enter the vitreous body and form a black fog of flies that blocks the vision.

Vitreous hemorrhage: The vitreous body itself has no blood vessels, but if its surrounding tissues bleed, the blood will flow into it, which can lead to eye floaters. For instance, bleeding can be caused by uveitis, optic nerve papillitis, tumors, and blows to the eye.

People with high myopia, previous eye trauma, and diabetes are more likely to have retinal detachment and vitreous hemorrhage, and they should be more alert than the general population.

If the following four signs appear, it may mean theres a serious problem such as retinal detachment, and you should seek medical attention as soon as possible:

We can check for eye floaters by ourselves at home. Just cover one eye and stare at a white wall with the other eye to see if any floaters can be spotted.

After you find floating objects in front of your eyes for the first time, you can see an ophthalmologist for a fundus examination. If it is confirmed to be a physiological form of floaters, then there is no need to worry too much, just keep observing the symptoms and follow up with the ophthalmologist regularly.

It is also very convenient to go to a hospital or clinic to check for eye floaters. The procedure is to dilate the pupils with some eye drops (dilating agent) first, wait for about half an hour, and then perform a fundus examination. It should be noted that the dilating agent will cause temporary blurred vision and photophobia, so it is recommended to wear sunglasses after the examination. In addition, it is best to have a family member or friend accompany you after the examination, as you should not drive with dilated pupils.

Eye floaters caused by vitreous degeneration alone will not go away, and there is no specific medicine to treat the condition. Therefore, it is not recommended to treat floaters if they only pose a general nuisance. When the dark shadows affect your vision, you can try to rotate your eyeballs, so that the floating objects in the vitreous bodies will leave the center of your vision.

In a small number of cases, the eye floaters are so dense that they seriously affect the vision. For such patients, there are two treatment options to consider:

Surgically, the vitreous fluid and floaters can be removed from the eye, and the old vitreous fluid is replaced with a salt solution. Since vitreous humor is mainly aqueous, there is no significant difference after the replacement. However, this procedure carries a high risk of complications, such as retinal detachment, retinal tears, and cataracts.

Laser therapy uses lasers to target the floating objects in the vitreous humor to break them down and shatter them, so as to improve the symptoms of eye floaters. However, this method is rarely used, as its effect varies from person to person. If theres an error when aiming the lasers, it may damage the retina.

If the condition of the patients eyes is relatively severe, such as having a fissure in the peripheral retina, a retinal laser surgery can be used to utilize the lasers coagulation effect to fix the retina around the fissure to the wall of the eyeball to prevent further deterioration into retinal detachment. If it is a vitreous hemorrhage, the patient can take hemostatic medication for about 3 to 6 months to allow the oozed blood to be absorbed gradually, and then undergo more complicated treatments, if the condition hasnt improved by then.

The first and foremost task in caring for eyes with floaters is to slow down the aging of the vitreous humor. Therefore, an eye floater patient should avoid staying up late and using electronic devices, such as cell phones and tablets, excessively, and should use desk lamps with soft light.

In addition, we should avoid strenuous and rapid head-turning exercises, such as bungee jumping and riding roller coasters, and excessive eyeball movements.

Furthermore, we can also take appropriate nutritional supplements, such as lutein, vitamin C, and foods rich in collagen (e.g. beef tendons). We can drink goji berry and chrysanthemum tea to slow down the aging of the vitreous humor.

References:

National Eye Institute, Kaohsiung Veterans General Hospital, Kuo General Hospital, and Lin Hsin Hospital

Continue reading here:

What Are These Things Floating in Front of My Eyes? - The Epoch Times

Data reinforces strong safety and efficacy for EYP-1901 as a potential six-month maintenance treatment for previously treated wet AMD

No dose limiting toxicities, no ocular serious adverse events (SAEs) and no drug-related systemic SAEs observed

Stable visual acuity and optical coherence tomography observed from a single treatment

Phase 2 clinical trial (DAVIO2) in wet AMD patient dosing anticipated in Q3 2022

WATERTOWN, Mass., July 15, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced 12-month data from the Phase 1 "Durasert and Vorolanib in Ophthalmology" (DAVIO) clinical trial evaluating EYP-1901, a sustained delivery anti-vascular endothelial growth factor (anti-VEGF) therapy targeting wet age-related macular degeneration (wet AMD) as a potential every six-month treatment. These data are being presented today at the American Society of Retina Specialists (ASRS) 2022 Annual Meeting by Rishi Singh, M.D., Staff Physician, Cleveland Clinic Florida, President Cleveland Clinic Martin Hospitals.

EyePoint Pharmaceuticals, Inc. logo

"The final 12-month results from the DAVIO clinical trial highlight EYP-1901's continued positive safety and efficacy profile with promising durability as a potential every six-month maintenance therapy for previously treated wet AMD," said Rishi Singh, M.D., a member of EyePoint's Scientific Advisory Board. "We are grateful to the patients, investigators and site staff who participated in the Phase 1 DAVIO trial."

"We are extremely pleased with the excellent safety and efficacy results from our Phase 1 DAVIO trial. There remains a significant opportunity for a safe and effective sustained delivery maintenance treatment in wet AMD, and the DAVIO trial demonstrates that EYP-1901 has the potential to maintain a majority of patients for up to six months with no supplemental anti-VEGF therapy," saidNancy Lurker, Chief Executive Officer ofEyePoint Pharmaceuticals. "We look forward to beginning to dose patients in the Phase 2 DAVIO2 clinical trial for EYP-1901 in wet AMD and anticipate top line data in the second half of 2023."

Story continues

The final twelve-month data presented from the Phase 1 DAVIO clinical trial showed no reports of ocular SAEs or drug-related systemic SAEs. There were no reported events of vitreous floaters, endophthalmitis, retinal detachment, implant migration in the anterior chamber, retinal vasculitis, posterior segment inflammation, or retinal vascular occlusive events. Additionally, updated data from the twelve-month follow-up confirm stable best corrected visual acuity (BCVA) (-4.12 ETDRS letters), stable central subfield thickness (CST) on optical coherence tomography (OCT) (-2.76 m), and an expected late increase in supplemental anti-VEGF therapy given the insert's expected drug depletion, with 35% of eyes supplement free up to twelve months versus 53% supplement free up to six months. Additionally, there continued to be positive treatment burden reduction of 74% at twelve months versus 79% at six-months.

EyePoint anticipates that the first patient in the twelve-month, randomized, controlled Phase 2 clinical trial (DAVIO2) of EYP-1901 for wet AMD will be dosed in Q3 2022. The trial is expected to enroll approximately 150 wet AMD patients previously treated with a standard-of-care anti-VEGF therapy and randomly assigned to one of two doses of EYP-1901 (approximately 2 mg or 3 mg) versus an on-label aflibercept control. EYP-1901 is delivered with a single intravitreal injection in the physician's office, similar to current FDA approved anti-VEGF treatments. The primary efficacy endpoint of the DAVIO2 trial is non-inferiority to the aflibercept control, as measured by change in BCVA six-months after the EYP-1901 injection. Secondary efficacy endpoints include change in CST as measured by OCT, time to first supplemental anti-VEGF, and safety. More information about the study is available at clinicaltrials.gov (identifier: NCT05381948).

About EYP-1901

EYP-1901 is being developed as an investigational sustained delivery treatment, initially in wet age-related macular degeneration (wet AMD)combining a bioerodible formulation of EyePoint's proprietary Durasert delivery technology with vorolanib, a tyrosine kinase inhibitor. Positive twelve-month safety and efficacy data from the Phase 1 DAVIO clinical trial of EYP-1901 showed no reports of ocular or drug-related systemic serious adverse eventsand no dose limiting toxicities with stable visual acuity and OCT. Further, 53% of eyes did not require supplemental anti-VEGF injections up to six months following a single dose of EYP-1901. A Phase 2 trial for wet AMD (DAVIO2) is expected in Q3 2022 and Phase 2 studies are planned for non-proliferative diabetic retinopathy and diabetic macular edema in 2H 2022 and 2023, respectively. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases.

About Wet AMD

Age-related macular degeneration (AMD) impacts as many as 11 million Americans. About 15% of those affected have neovascular or wet AMD - the hallmark of which is fluid and bleeding in the center of the retina, which may lead to irreversible vision loss. The majority of patients with wet AMD require intravitreal injections every month or two to control the disease. This intense treatment regimen represents an ongoing challenge for patients, caregivers, and physicians.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Forward Looking Statements

EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint's actual results to be materially different than those expressed in or implied by EyePoint's forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a sustained delivery intravitreal anti-VEGF treatment for serious eye diseases, including wet age-related macular degeneration; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the success of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of our commercialized products, YUTIQ and DEXYCU; market acceptance of our products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; the continued impact of the COVID-19 pandemic on EyePoint's business, the medical community and the global economy; and the impact of general business and economic conditions. More detailed information on these and additional factors that could affect EyePoint's actual results are described in EyePoint's filings with theSEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investors:

Christina TartagliaStern IRDirect: 212-698-8700christina.tartaglia@sternir.com

Media Contact

Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/eyepoint-pharmaceuticals-announces-positive-12-month-safety-and-efficacy-data-from-phase-1-davio-clinical-trial-evaluating-eyp-1901-for-the-treatment-of-wet-amd-301587236.html

SOURCE EyePoint Pharmaceuticals, Inc.

Read the original here:

EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment...

Adverum Biotechnologies, Inc.

- Study participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous aflibercept expression levels through three years

- Mean best-corrected visual acuity and central subfield thickness were maintained or improved in subjects treated with ADVM-022

-The Phase 2 LUNA trial is expected to dose the first subject in the third quarter of 2022 and preliminary data anticipated throughout 2023

REDWOOD CITY, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new data from the OPTIC study treating wet age-related macular degeneration (wet AMD) during the American Society of Retina Specialists (ASRS) 2022 Annual Meeting. New data presented are as of February 24, 2022 and include best-corrected visual acuity (BCVA) and central subfield thickness (CST) maintenance, as well as reduction in CST fluctuation after a single, in-office intravitreal (IVT) injection of ADVM-022, ixoberogene soroparvovec (Ixo-vec), in subjects requiring frequent anti-VEGF injections for their wet AMD.

We are pleased to present our findings on BCVA and CST from the OPTIC trial, establishing that maintenance in both BCVA and CST, as well as a reduction in CST fluctuations, were sustained through at least two years, suggesting the long-term durability of Ixo-vec after a single IVT injection, stated Richard Beckman, M.D., chief medical officer at Adverum Biotechnologies. As several publications have recently highlighted, retinal CST fluctuations over time are associated with poor long-term visual outcomes for patients. The combination of durable maintenance of BCVA and reduced CST fluctuations in subjects who previously required frequent IVT injections further support our belief that Ixo-vec can provide better long-term benefit for wet AMD patients. We are excited by the possibility of extending the treatment benefit for this lifelong disease from the order of months to the order of years.

Story continues

Data Highlights as of February 24, 2022

OPTIC trial participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous therapeutic aflibercept protein expression levels through three years following a single, in-office intravitreal injection of ADVM-022.

Mean BCVA (ETDRS) change from baseline to last visit was maintained or improved for two years post-treatment with ADVM-022 across both the 6x10^11 vg/eye (6E11) and 2x10^11 vg/eye (2E11) dose levels.

Mean CST was reduced by 55.7 m at the 6E11 dose (p=0.014) and by 95.9 m at the 2E11 dose (p=0.015) and maintained for two years following treatment across both ADVM-022 dose levels.

In the 2E11 dose in subjects with neutralizing antibodies (NAb) titers <1:125, subjects demonstrated a mean BCVA improvement of 5.2 letters for two years following treatment with ADVM-022.

ADVM-022 was well tolerated, with no participants in the 2E11 dose group requiring any topical corticosteroids to treat inflammation at most recent follow-up.

No evidence of correlation between baseline NAbs and occurrence of inflammation or other safety events has been observed.

We are excited to present these encouraging data, showing continuous and stable aflibercept expression for over three years in our OPTIC trial in subjects with wet AMD, commented Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies. As we recently announced, we completed our IND amendment with the U.S. Food and Drug Administration, received European Medicines Agency PRIME designation, and are preparing to initiate the Phase 2 LUNA trial of Ixo-vec in wet AMD. The LUNA trial was designed after a detailed data review from all 55 participants treated to date with a single ADVM-022 injection. Four new enhanced prophylactic steroid regimens will be evaluated in LUNA with the aim of providing steroid coverage during the period of peak immunogenicity. Our goal is to enhance the safety profile of ADVM-022 while building upon the impressive efficacy profile we continue to see in the OPTIC trial. We plan to dose the first subjects in the third quarter of 2022 and anticipate preliminary data from LUNA throughout 2023 and look forward to providing more detail on the expected timeline once we can assess the pace of enrollment.

The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 trial evaluating two doses of Ixo-vec, including 2E11 and a new, lower 6x10^10 vg/eye (6E10) dose, in up to 72 patients with wet AMD. The LUNA trial will assess four new enhanced prophylactic steroid regimens, including local steroids and combinations of local and systemic steroids to test the relative contribution of local versus systemic AAV exposure on ocular inflammation. Specific regimens include topical difluprednate (Durezol), IVT Ozurdex, or a combination of either topical Durezol or IVT Ozurdex with oral prednisone.

The trial will randomize the participants equally between the 2E11 and 6E10 Ixo-vec doses across four prophylactic steroid regimens and will be conducted at approximately 40 sites in the U.S. and Europe. The primary endpoints will be similar to the OPTIC trial and focus on mean change in BCVA and CST from baseline to one year, and incidence and severity of adverse events. Other data points will include protein expression of aflibercept starting at 10 weeks and an interim analysis at 26 weeks. The study will also evaluate the effectiveness and tolerability of the prophylactic steroid regimens.

As an investigator in OPTIC, I have observed the potential of ADVM-022 to significantly reduce the treatment burden for my patients with neovascular age-relatedmacular degeneration. In the latest data from the OPTIC trial, we have seen a manageable safety profile, robust aflibercept expression, and sustained anatomical improvements after two years following a single 2E11 dose of ADVM-022, said Dante Pieramici, M.D., partner, California Retina Consultants, and presenter of the data at ASRS. I look forward to participating as a LUNA investigator and building on the efficacy and safety profile in OPTIC with a new, lower 6E10 dose and to determine an optimal prophylactic steroid regimen for patients.

About Wet Age-Related Macular Degeneration

Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD. Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with this condition. The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.

About OPTIC Trial of ADVM-022 in Wet AMD

ADVM-022 is Adverums clinical-stage gene therapy product candidate being developed for the treatment of wet AMD. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach), ADVM-022 has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD.

The OPTIC trial is designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of ADVM-022 in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment-experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, ixoberogene soroparvovec (Ixo-vec), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit http://www.adverum.com.

Forward-looking Statements

Statements contained in this press release regarding events or results that may occur in the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding Adverums plans to initiate a Phase 2 study in wet AMD to investigate the 2x10^11 vg/eye dose and a lower 6x10^10 vg/eye dose of ADVM-022, as well as new enhanced prophylactic steroid regimens, including local steroids and a combination of local and systemic steroids, planned for the third quarter of 2022, as well as the benefits Adverum expects from this trial, and the timing of preliminary data from the LUNA trial. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation: Adverums novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials; regulatory uncertainties; enrollment uncertainties the results of early clinical trials not always being predictive of future clinical trials and results; and the potential for future complications or side effects in connection with use of ADVM-022. Additional risks and uncertainties facing Adverum are set forth under the caption Risk Factors and elsewhere in Adverums Securities and Exchange Commission (SEC) filings and reports, including Adverums Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 12, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Corporate & Investor Inquiries

Anand ReddiVice President, Head of Corporate Strategy and External Affairs & EngagementAdverum Biotechnologies, Inc.T: 650-649-1358E: areddi@adverum.com

Media

Megan TalonAssociate Director, Corporate CommunicationsAdverum Biotechnologies, Inc.T: 650-649-1006E: mtalon@adverum.com

Read more:

Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022...

Diabetes causes a persons blood sugar levels to become too high, which must be handled carefully to prevent further complications. Unfortunately, the condition doesn't always produce obvious symptoms. Excessive sweating at night, however, could be a sign that high blood sugar has damaged the nerves.

Excessive can both be a sign of low blood sugar levels and blood sugar damage to nerves.

The most common reason for unusual sweating in people with the condition, however, is diabetes-related nervous system damage.

According to the American Diabetes Association, approximately half of people with diabetes experience some level of nerve damage.

When nerve damage occurs, known as autonomic neuropathy, it occasionally affects the sweat glands.

READ MORE:Diabetes: Summer foods that could spike blood sugar

High blood sugar and high levels of fat, such as triglycerides, can damage the nerves or the blood vessels that nourish the nerves.

This may produce several different symptoms depending on which of the bodys functions are affected.

The National Institute of Diabetes and Digestive and Kidney Diseases says: Damage to the nerves that control your sweat glands may cause you to sweat a lot at night or while eating.

Your sweat glands may not work at all, or certain parts of your body may sweat while other parts are dry.

DON'T MISS:

If your sweat glands do not work properly, your body may not be able to control its temperature.

Sometimes nerve damage prevents signals from being sent to different parts of the body, which can result in numbness.

Other types of discomfort may occur, such as sharp pains, cramps, muscle weakness or sensitivity to touch.

Depending on the nerves affected, neuropathy can cause these sensations in the hands, feet, and legs.

READ MORE:Diabetes warning: Do not 'overindulge' in a particular type of fruit

The Centers for Disease Control and Prevention says: Nerve damage can cause health problems ranging from mild numbness to pain that makes it hard to do normal activities."

There are several steps that can help prevent diabetes, but the most logical starting point is diet.

It is advisable to choose whole grain products over refined grained ones and other highly processed carbohydrates.

This is because refined carbohydrates can increase blood triglycerides, and blood sugar levels and cause insulin resistance, which are major risk factors for diabetes.

There are also many benefits to regular physical activity for blood sugar control, as it can help keep them within a healthy range for up to 48 hours.

Plants, which provide a wealth of vitamins, minerals and carbohydrates, are good energy sources for the body.

Dietary fibre can also slow the absorption of sugars and interfere with the absorption of dietary cholesterol.

These food sources also promote weight loss, which in turn may lower the risk of diabetes.

See the rest here:
Diabetes symptoms: The sign of nerve damage that often strikes at night - severe - Express

What is Diabetes?

Diabetes is the seventh-leading cause of death in the United States.

Diabetes is a long-lasting health condition that affects how your body turns food into energy. With diabetes, your body either doesnt make enough insulin or cant use it as well as it should.

Most of the food you eat is broken down into sugar (also called glucose) and released into your bloodstream. When your blood sugar goes up, it signals your pancreas to release insulin. Insulin acts like a key to let the blood sugar into your bodys cells for use as energy.

If you have diabetes, your body either doesnt make enough insulin or cant use the insulin it makes as well as it should. When there isnt enough insulin or cells stop responding to insulin, too much blood sugar stays in your bloodstream.

Over time, that can cause serious health problems, such as heart disease, vision loss, and kidney disease.

Types & symptoms

Type 1 diabetes is thought to be caused by an autoimmune reaction (the body attacks itself by mistake) that stops your body from making insulin. Approximately 5-10% of the people who have diabetes have type 1.

Symptoms of type 1 diabetes often develop quickly. Its usually diagnosed in children, teens, and young adults. Currently, no one knows how to prevent type 1 diabetes.

People who have type 1 diabetes may also have nausea, vomiting, or stomach pains. Type 1 diabetes symptoms can develop in just a few weeks or months and can be severe.

Type 2 diabetes occurs when your body doesnt use insulin well and cant keep blood sugar at normal levels. About 90-95% of people with diabetes have type 2. It develops over many years and is usually diagnosed in adults; however more children, teens, and young adults are developing type 2 diabetes.

With healthy lifestyle changes, such as eating healthy food, losing weight, and being active Type 2 diabetes can be prevented or delayed.

Some people dont notice any symptoms at all. Because symptoms are hard to spot, its important to know the risk factors for type 2 diabetes. Make sure to visit your doctor if you have any of them.

Gestational diabetes develops in pregnant women who have never had diabetes. If you have gestational diabetes, your baby could be at higher risk for health problems.

Gestational diabetes usually goes away after your baby is born but increases your risk for type 2 diabetes later in life. Your baby is more likely to develop type 2 diabetes later in life too. Gestational diabetes (diabetes during pregnancy) usually doesnt have any symptoms.

If youre pregnant, your doctor will test you for gestational diabetes between 24 and 28 weeks of pregnancy.

Symptoms & risk factors

Diabetes symptoms may include an increase in thirst, urinating a lot, lose of weight without trying, increased hunger, blurry vision, dry skin, feeling tired, numbness or tingling in your hands or feet, sores or wounds that heal slowly. If you have any of the following diabetes symptoms, see your doctor.

Risk factors for developing type 2 diabetes can include a history of prediabetes, being over the age of 45, overweight, having a parent or sibling with type 2 diabetes, or ever had gestational diabetes, are physically active less than 3 times a week.

There isnt a cure yet for diabetes, but losing weight, eating healthy food, and being active can help. Knowing diabetes risk factors and taking medicine as directed, you can prevent or delay type 2 diabetes with lifestyle changes.

Diabetes self-management education, support, and keeping your health care appointments can reduce the impact of diabetes on your Life! Please see the American Diabetes Association https://www.diabetes.org/, for further information .

Source: Centers for Disease Control Prevention.

Michaella Quallen is with the Clinton County Health District.

Read the rest here:
Diabetes: Symptoms, risks, and prevention - Wilmington News Journal, OH

While most of us are familiar with type 1 and type 2 diabetes, you may not have come across the term type 3 diabetes before. First things first, this is not to be confused with type 3c diabetes, which is something else entirely. It is, however, related to insulin resistance in the brain.

Being diagnosed as insulin resistant generally means that someone is either prebiabetic or has type 2 diabetes. But scientists have proposed that it can also result in the brains neurons lacking glucose, which is needed for proper function, and this can lead to symptoms of Alzheimer's disease.

While type 3 diabetes is not an officially recognised health condition, in 2008 Dr Suzanne de la Monte and Dr Jack Wands of Brown University put forward a proposal that Alzheimers disease could be termed type 3 diabetes due to its strong links with insulin resistance. Insulin resistance may be a leading cause of dementia, as this glucose deficiency in the brain leads to symptoms such as loss of memory, decrease in judgment and reasoning skills.

Type 3 diabetes is not a medically recognised term and is not something doctors use for diagnostic purposes. However, insulin resistance and decreased insulin signaling in the brain may play a role in the development of Alzheimer's disease. Not to mention, the risk of developing Alzheimer's disease is significantly higher in those with type 2 diabetes. As such, the term type 3 diabetes has been colloquially used by some in the field to illustrate these links.

A study in the Lancet journal of Neurology (opens in new tab) links diabetes with declining brain health and indicates that treatments that restore cerebral insulin function may offer therapeutic benefits to those with Alzheimer's disease.

Dr. William H Frey II, an Alzheimer's specialist at the Health Partners Center for Memory and Aging (opens in new tab), also explains that the disease causes cognitive decline in patients. Alzheimer's is a degenerative brain disease that accounts for more than 60% of the cases of dementia, he tells Live Science. It is characterized by memory loss, especially short-term or recent memories, cognitive decline and changes in behavior, all of which get progressively worse over time.

Dr Tariq Mahmood, a doctor and medical director at Concepto Diagnostics (opens in new tab), adds: Type 3 diabetes isnt an officially recognised health condition and isnt used for diagnostic purposes. It differs from type 1 diabetes and type 2 diabetes, which cause blood sugar levels to become too high due to issues with a hormone called insulin. Some scientists hypothesize that insulin dysregulation in the brain causes dementia and use type 3 diabetes as a term to describe Alzheimers disease a progressive neurological condition which is the most common cause of dementia.

Mahmood explains that while type 3 diabetes is not an official diagnosis, doctors can diagnose Alzheimers disease, which affects multiple brain functions gradually over the course of many years. Minor memory problems are usually the first sign, he says. More specific symptoms can include confusion, difficulty planning, disorientation, getting lost and personality changes.

Early to moderate symptoms of Alzeimers include:

These symptoms usually develop to a point that patients cannot swallow, lose bowel control and eventually pass away. Often people with Alzeimers die from aspiration pneumonia. This develops when food or liquids pass into the lungs instead of air due to problems with swallowing, as is stated by the National Institute of Aging (opens in new tab).

Dr Frey tells us that Alzheimers is best diagnosed by a neurologist who is familiar with neurodegenerative memory disorders. Diagnostic procedures may involve taking a complete history, blood tests, brain imaging, neuropsychological testing, etc. to help rule out other disorders that may produce somewhat similar symptoms, he says.

A review on insulin resistance in the Frontiers in Neuroscience (opens in new tab) journal indicates that insulin links multiple conditions together, such as obesity, dementia and diabetes, and recommends the potential use of antidiabetic medication to treat dementia. Additionally, the review explores the link between dementia and a high allostatic load, which is the burden created by stress, life events and other environmental challenges.

Mahmood tells us that while the science is unclear on the specific cause of Alzeimers disease, a combination of factors may be at play. Its widely believed that age-related neurological changes combined with genetic, environmental, and lifestyle factors can contribute toward it, he says. Age is the most important known risk factor for Alzheimers disease due to, among other things, atrophy in parts of the brain. Atrophy is the wasting of a muscle, meaning it can shrink, thin or be outright lost.

But Dr Frey explains that general aging is not the only risk factor associated with the development of Alziemers disease. Aging is the major risk factor for Alzheimer's disease, but Alzheimer's is not a normal part of aging, he says. Family history of Alzheimer's and genetic changes can also increase the risk, but individuals without a family history of the disease can still get Alzheimer's disease. A history of moderate traumatic brain injury can also significantly increase the risk for developing Alzheimer's disease.

Finally, type 2 diabetes doubles the risk for developing Alzheimer's disease. This is likely due to the fact that in both diabetes and Alzheimer's disease, there is a deficiency of insulin signaling.

He goes on to explain that In Alzheimer's disease, this insulin signaling deficiency occurs in the brain and leads to a loss of brain cell energy. Without sufficient insulin signaling, blood sugar is not taken into brain cells and metabolized normally.

Loss of brain cell energy means that the brain can no longer carry out memory and cognitive functions normally and also can not produce the parts of brain cells needed to replace those that wear out over time leading to degeneration of the brain itself.

Unhealthy lifestyles, including lack of exercise, poor diet and lack of sleep, likely also increase the risk for Alzheimer's disease, he says.

Dr Freys research has been pioneering in the area of insulin resistance and Alzheimer's. In 2022, he released a study in the Pharmaceuticals (opens in new tab) journal indicating that intranasal insulin (insulin administered up the nose) can help with cerebral glucose hypometabolism, which is a characteristic that is commonly found in those with degenerative cognitive disorders, as well as type 2 diabetes.

Because insufficient insulin signaling contributes to loss of brain cell energy in individuals with Alzheimer's disease, [we] first proposed intranasal insulin as a treatment for Alzheimer's disease about 22 years ago, he says. Intranasal insulin delivers and targets insulin to the brain along the nerves involved in smell without altering the blood levels of insulin or blood sugar.

But while clinical trials have shown that non-invasive intranasal insulin increases brain cell energy and improves memory in normal healthy adults, as well as those with mild cognitive impairment or Alzheimer's disease, it needs further development and testing to sufficiently demonstrate its safety and efficacy before it can be considered for regulatory approval and made available.

Dr Mahmood tells us that while there is regrettably no cure for Alzheimer's disease, treatments for those with the condition are available. There are medicines and treatments that can reduce symptoms on a temporary basis, he says. The two main medicines right now are acetylcholinesterase (AChE) inhibitors, which help nerve cells communicate with each other, and memantine, which blocks the effects of excessive glutamate this is a neurotransmitter released by nerve cells which plays a major role in learning and memory.

For people who begin to show aggression or distress, antipsychotic medicines can also be prescribed. For treatments, cognitive rehabilitation and cognitive stimulation therapy can help maintain memory and problem-solving skills.

A review in the Journal of Alzheimer's Disease (opens in new tab) indicates meditation may help with the prevention of Alzheimers disease, as it reduces allostatic load, which has been linked to the development of several cognitive disorders. Just 12 minutes of Kirtan Kriya meditation per day was shown to improve sleep, decrease depression, reduce anxiety, down regulate inflammatory genes, upregulate immune system genes, and improve insulin and glucose regulatory genes.

Dr Mahmood tells us that general healthy living is recommended to reduce your risk too, although other risk factors are uncontrollable. Unfortunately, theres no way to prevent Alzheimers disease at the moment, he says. Living a healthy lifestyle might lessen your risk, but age-related neurological changes and genetic factors are impossible to work around. Cardiovascular disease has been linked with an increased risk of Alzheimer's disease, so eating a balanced diet, making sure you get 150 minutes of exercise per week, limiting alcohol consumption and stopping smoking are all worthwhile.

Our easy Mediterranean diet plan and 7-day plant-based diet meal plan have lots of ideas to help you to eat a more balanced diet.

Dr Frey agrees that general healthy living is a wise course of action in working to avoid Alzheimer's disease. He also recommends protecting your head. Maintaining a healthy lifestyle including regular physical activity, avoiding head injury by wearing your seatbelt while in vehicles and a helmet during sports, consuming a healthy diet and remaining socially active can all help to reduce your risk for Alzheimer's disease, he says.

This article is for informational purposes only and is not meant to offer medical advice.

Original post:
Type 3 diabetes: symptoms, causes and treatments - Livescience.com

Alexandra drops TD1 kits off to a Yonkers school (Photo by Jason Malkin)

An Ardsley teen is working to make life with type 1 diabetes easier on local kids. Alexandra Malkin, a rising senior at Ardsley High School, started T1D Kits for Kids to provide free essential health supplies (along with a few small treats) to elementary-aged children. And people are taking notice she was recently named Hero of the Day by Good Day New York for her work.

Malkin saw firsthand what kind of hardships kids face with juvenile diabetes after her childhood friend was diagnosed with the condition at age 9. As I watched her life change extremely quickly, I began to understand the true impact that diabetes can have on someones life especially at a very young age, she told River Journal.

The experience stayed with her. Malkin decided to focus on diabetes once she was accepted into her schools science research program, a 3-year elective that allows students to dive into specific research areas. After reading various articles on past diabetic studies during the year, I was sure I wanted it to be what I would study for the remainder of my time in the program influencing the two summer research projects I have been a part of involving diabetes.

While immersing herself in the science, Malkin also discovered that the high costs associated with type 1 diabetes can be especially detrimental to children. More recently, I found out from a friend that their cousin who works at an elementary school in Michigan has seen a lot of diabetic students who arent able to afford the basic diabetic technology, she said. As I looked into this issue more, I noticed extremely high prices of diabetic kits sold by large diabetes companies more than any underprivileged family could afford.

This sparked the idea to provide children with the devices and medical supplies needed for free. Her kits include glucose monitors, lancets, Band-Aids, batteries, and glucose tabs, basic and necessary tools to stay healthy throughout the day. While those items will make many parents happy, Malkin doesnt forget her main focus: kids with juvenile diabetes. She tucks a few treats inside each basket to make them smile. I also wanted to address the desire for comfort from young type-1 diabetics by including teddy bears, sugar-free candy, and bracelets, pins, that help them embrace their T1D identity.

Since kicking off in January, Malkin has donated batches of kits to three different elementary schools, where she works with nurses to identify those who would benefit from them most. The greatest amount of newly-diagnosed type 1 diabetics usually are found within that age group (kindergarten 4th grade), she noted. The kits have been specialized to appeal to this

age group as well. Shes working to keep relationships with the schools, and has been sent photos of the recipients holding the kits and smiling ear-to-ear.

Malkin hopes to expand the program outside Westchester in the future and has applied for grants to continue funding and upgrading her kits. And she wants to help connect children with juvenile diabetes through their stories. I also have an idea to create a diabetes advice book that would include advice from experienced type 1 diabetics to help the younger diabetics make a smoother transition and feel like they arent alone.

To help keep the program going, Malkin said sharing her work with others and making a donation would go a long way. The only way to truly make my organization grow is to promote necessary funding and recognition for the work of T1D Kits for Kids and the concept behind it, she said. With these contributions, I can achieve the goals I have for the non-profit and expand my impact to the larger diabetic community.

Visit t1dkitsforkids.org to learn more or to make a donation.

Read more:
Local Teen Brings Smiles and Health Kits to Kids with Diabetes - River Journal Staff

When you are traveling by vehicle to your destination, you should:

Once you reach your destination:

One of the most important aspects of managing Type 2 diabetes is for the patient to test their blood glucose level, usually twice a day. This could be more for some patients, depending on the care plan from their physician.

In an article in Healthline, Lisa Harris, CDE, RN at Rush University Medical Center in Chicago said that many patients with type 2 diabetes would likely benefit from testing more frequently. "Testing your blood sugar can be extremely informative for people when they're trying to prevent the need for further medication, like insulin," Harris said. "Even if they're only taking metformin, seeing for themselves how certain types of foods affect their blood sugar can have the biggest impact on motivating them to make changes in their diet."

In addition, when traveling, healthy eating tends to become more difficult to regularly sustain. People will usually eat out more and have less time to plan healthy meals or have fewer healthy options from which to choose. There's also less time to ensure proper nutrition and exercise which is important for managing diabetes.

"For people with diabetes, having their blood glucose readings sent to a provider is even more important when they travel because their diet might not be as healthy, eating times and patterns may shift, and other metabolic stressors related to traveling," said Dr. Bill Lewis, a leading telehealth consultant. "The iGlucose is the perfect traveling companion for people with diabetes so their test results are still being transmitted seamlessly to their provider."

Many of today's devices for at-home remote patient monitoring (RPM) rely on Bluetooth technology or Wi-fi paired to an app on a smartphone. These connections especially low-energy Bluetooth, can fail and may not reliably or securely deliver health data to providers.

The iGlucose from Smart Meter has proprietary cellular technology that utilizes the fast and secure 4/5G AT&T IoT network for reliable transmissions every time. With the cellular-enabled iGlucose, the measurement is sent immediately to the patient's provider with no extra steps required by the patient.

About Smart Meter, LLC

Now serving more than 100,000 patients, Smart Meter is the leading supplier of cellular-enabled virtual care technologies that include the iGlucose, iBloodPressure, iPulseOx, iScale, and SmartRPMcloud platform, as well as data, and services. Smart Meter's remote patient monitoring solutions are recognized as the standard for the RPM industry and are regarded for their high patient retention and satisfaction. The unique combination of reliable health data, patient-friendly devices, and platform integrations enable and enhance RPM, CCM, Employee Wellness, Population Health, and Telehealth programs for more than 300 RPM distribution partners across the United States. For more information, visitSmartMeterRPM.com

Smart Meter, LLC

Media Contact

5501 W. Waters Ave., Suite 401

Keith Tolbert

Tampa, FL 33602

[emailprotected]

813-773-4080

336-509-8024

SOURCE Smart Meter, LLC

The rest is here:
Diabetes Travel Essentials and Tips for the Approximately 21 Million Americans that Must Manage Their Diabetes While on Vacation - PR Newswire

News Release

Thursday, July 14, 2022

NIH-funded clinical trial finds that starting with a cheaper drug and switching to a more expensive drug as needed leads to good vision outcomes in diabetic macular edema.

Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug. The main complication of diabetic macular edema, fluid build-up in the retina that causes vision loss, is commonly treated with anti-vascular endothelial growth factor (VEGF) drugs.

The trial was funded by the National Eye Institute (NEI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both part of National Institutes of Health. Results of the trial, which examined a stepped regimen of anti-VEFG drugs Avastin (bevacizumab) and Eylea (aflibercept), were published today in the New England Journal of Medicine.

Our study showed that switching treatments when needed is a reasonable strategy, said Chirag Jhaveri, M.D., Austin Research Center for Retina, Texas, the lead study author. Insurance companies often require clinicians to start with the less expensive treatment, so we really wanted to see how a specific treatment strategy using this approach would affect patient care.

Diabetic macular edema is caused by diabetes-related alterations to retinal blood vessels. Symptoms include blurred vision. If untreated, vision loss can become permanent and progress to blindness. Retinal injections of anti-VEGF drugs can restore vision. The DRCR Retina Network previously showed that Avastin and Eylea improve visual acuity in people with diabetic macular edema. However, while Eylea is approved by the U.S. Food and Drug Administration to treat diabetic macular edema and results in better visual outcomes on average, off-label Avastin is much less expensive and is sometimes required by insurers as a first-line treatment.

The study enrolled 270 participants with diabetic macular edema, some of whom received treatments in both eyes. At enrollment, all had best-corrected visual acuity between 20/50 and 20/320. Half the study eyes were assigned to Eylea from the start, and half were assigned to start with Avastin. For participants who needed treatment in both eyes, each eye started treatment with a different drug. Participants received either Avastin or Eylea injections every four weeks for 24 weeks. If eyes assigned Avastin failed to reach the pre-set improvement benchmarks starting at 12 weeks, the eye was switched to Eylea.

After 24 weeks, physicians could taper down the frequency of injections as appropriate to maintain visual acuity. The study collected information about participants retinal structure and visual acuity for two years.

After two years, eyes in both groups had similar visual acuity outcomes, improving on average approximately three lines on an eye chart, compared to the trials start. In the Avastin group, 70% of eyes switched to Eylea during the study.

While most participants on Avastin eventually switched to Eylea, they still had improvement during those initial weeks, even if they didnt hit our pre-set benchmarks, said Adam Glassman of the Jaeb Center for Health Research and director of the DRCR Retina Network coordinating center. There are large cost disparities between these drugs, so differences in treatment strategies may have substantial cost implications.

Weve demonstrated here one method to managing a step treatment, where the outcomes are similar to the best existing treatment protocol with Eylea, said Jennifer Sun, M.D., M.P.H., of Joslin Diabetes Center and Harvard Medical School, Boston, and chair of diabetes initiatives for the DRCR Retina Network. Any time we can add to a clinicians toolbox, whether its a new medication or a new approach to using existing medications, as in this study, its a benefit for patients.

The study was supported by NEI (EY014231) and NIDDK through the Special Diabetes Program for Type 1 Diabetes Research. Clinical trial number NCT03321513.

NEI leads the federal governments research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Jhaveri CD, Glassman AR, Ferris FL, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK, DRCR Retina Network. Aflibercept monotherapy versus bevacizumab first followed by aflibercept if needed for treatment of center-involved diabetic macular edema. NEJM. July 14, 2022.

###

Continued here:
A type of 'step therapy' is an effective strategy for diabetic eye disease - National Institutes of Health (.gov)

International Diabetes Federation (IDF) reports one in five Google searches for terms related to diabetes reveal inaccurate information about the condition and how to manage its complications, showing the lack of reliable diabetes education available for those who have or may have the condition.

The number of people living with diabetes continues to rise around the world, with the latest IDF estimatesindicating that one in nine adults will be affected by 2030. The necessity for reliable, accessible and accurate data on the condition can be a matter of life or death for people with serious cases of diabetes.

When diabetes is undetected and inadequately treated especially treated through home remedies which are reliant on misinformed articles on diabetes education people with diabetes are at higher risk of serious and life-threatening complications.

This is putting added strain on healthcare systems that, following two years of a global pandemic, are already struggling.

Out of 30 search results (the first results page for each search term), six links directed users to unverified information for different diabetes terms.

Terms including diabetes, how to manage diabetes and diabetes symptoms featured results and answers to questions from non-medical sources including Wikipedia, Amazon and Facty the last of which showed an article on home remedies for diabetes.

In one case, when searching for the term diabetes, users were shown an advert from an organisation that aims to wean people living with diabetes from insulin this can be extremely dangerous for those with type 1 diabetes, because if they experience an interruption in their supply of insulin, it can be potentially fatal.

Researchers of this data strongly advocate that decisions to reduce insulin treatment should be taken in close consultation with a qualified healthcare professional, preferably a specialist in diabetes.

According to IDF figures, an estimated 44.7% of adults living with diabetes (240 million people) across the world are undiagnosed with the overwhelming majority having type 2 diabetes.

Professor Andrew Boulton, IDF President, says: Many people now turn to Google and the internet for advice, so its worrying that misinformation about diabetes is still rife online.

With the prevalence of diabetes showing no signs of declining, ensuring that healthcare professionals are equipped to provide the best possible care and that people with diabetes can make informed decisions about their self-care is more important than ever. We need quality education today to help protect tomorrow.

IDF is committed to facilitating learning opportunities for all people concerned by diabetes, so their newonline platformhas been launched providing free interactive courses to help people with diabetes and their carers to understand and manage their condition.

The first course available provides an introduction to diabetes, explaining what it is, how it works and the common warning signs and risk factors.

For healthcare professionals, theIDF School of Diabetesoffers a selection of free and premium online courses that help them to keep up-to-date with various aspects of diabetes education, management and treatment.

Editor's Recommended Articles

Read more:
Diabetes education: one in five search results for diabetes lack reliable information - Open Access Government